MET amplification is also detected in other oncogene-addicted NSCLCs including those with ALK rearrangements, in which 15% of tumour biopsies from patients relapsing on next-generation ALK inhibitors detected MET amplification [23]. The gene discussed is ALK; the disease is neoplasm.